# Efficacy and Safety Study of MYOBLOC in the Treatment of Sialorrhea in Pediatric Subjects

> **NCT05097079** · PHASE3 · WITHDRAWN · sponsor: **Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC**

## Conditions studied

- Sialorrhea

## Interventions

- **DRUG:** MYOBLOC Low Dose
- **DRUG:** MYOBLOC High Dose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05097079
- **Lead sponsor:** Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-11
- **Primary completion:** 2023-05
- **Final completion:** 2023-05
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Company/sponsor business decision
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05097079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05097079, "Efficacy and Safety Study of MYOBLOC in the Treatment of Sialorrhea in Pediatric Subjects". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05097079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*